Correction: Heat shock protein 27 phosphorylation state is associated with cancer progression
Maria Katsogiannou, Claudia Andrieu, Palma Rocchi
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMitochondrial Function and Pathology · Metabolomics and Mass Spectrometry Studies · Endoplasmic Reticulum Stress and Disease
The conflict of interest statement was erroneously given as “The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.” The correct conflict of interest statement is “The University of British Columbia has submitted patent applications on Apatorsen, an antisense inhibitor of Hsp27, listing PR as an inventor. This IP has been licensed to OncoGenex Technologies, a Vancouver-based biotechnology company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The original article has been updated.